Suggestions
Shidong Jia
Founder & Global CEO, Predicine
Shidong Jia is the Founder and Global CEO of Predicine, a company specializing in precision medicine through innovative liquid biopsy technologies. He holds both an MD and a PhD, having completed his education at Harbin Medical University and Peking Union Medical College, followed by postdoctoral training at the Dana-Farber Cancer Institute and Harvard Medical School.
Before founding Predicine in 2015, Jia had a notable career in oncology research. He led oncology biomarker strategies and drug development at Genentech, where he notably identified p110beta as a drug target for PTEN-deficient tumors, which contributed to the clinical development of p110beta inhibitors. His prior experience also includes senior research roles at Novartis and Harvard University, focusing on translational and clinical cancer research.
Under his leadership, Predicine has developed a proprietary combination of cell-free DNA and RNA technologies for liquid biopsies, aimed at enhancing molecular diagnostics and supporting clinical trials globally. The company's mission is to empower the healthcare ecosystem through innovation, and it operates facilities in both the United States and China, collaborating with major biopharmaceutical companies to advance personalized healthcare solutions.1234
Highlights
Dear Connections,
I wanted to share an opportunity within my network. Organizational changes at Genentech led to the departure of some of my old colleagues who are highly skilled professionals from the Oncology Biomarker Development group. Genentech is known for hiring "the best and brightest" and has cultivated a team of exceptional individuals, some of whom are now seeking new opportunities due to organizational restructuring.
If your organization is seeking individuals with expertise in biomarker development, clinical trial, CDx development or related fields, I encourage you to consider reaching out to these talented professionals. They bring not only extensive skills and experience but also a proven track record of excellence.
Let's help these outstanding professionals transition smoothly into their next roles. Please feel free to connect with me or send me a message if you're interested in learning more about these individuals or discussing potential opportunities.
Best regards, Shidong
Thrilled to share some exciting news: Our PredicineBEACON Minimal Residual Disease (MRD) study in Hepatocellular Carcinoma (HCC) received a highlight in the ASCO Daily News during the ASCO-GI24 conference. This is a significant milestone in our journey to advance cancer care.
In this study, PredicineBEACON MRD assay effectively measured postoperative MRD using plasma samples in a cohort of patients with resectable HCC and demonstrated a compelling correlation between ctDNA MRD status and key patient outcomes - Relapse-Free Survival (RFS) and Overall Survival (OS).
The findings from this research are not just numbers; they represent a potential paradigm shift in how we approach post-surgical care and monitoring in HCC. It's an honor to be part of a team that's pushing the boundaries of oncology research and offering new hope to patients. #MRD #PredicineBEACON #HCC #ASCO #ASCOGI24
Learn more about our study here: https://lnkd.in/ghd6dmvW
Read about our highlight in the ASCO Daily News here: https://lnkd.in/gXftza4y
